Foghorn Therapeutics

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly

INDIANAPOLIS and CAMBRIDGE, Mass. , Dec. 13, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Foghorn Therapeutics Inc. (Nasdaq: FHTX), today announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control ® platform.

Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform

-- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma

Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update

David Millan, PhD, VP of Chemistry, to present overview of company's proprietary protein degrader platform and its clinical stage asset, FHD-609, a potent and selective heterobifunctional degrader of BRD9 David Millan, PhD, VP of Chemistry, to present overview of company's proprietary protein degrader platform and its clinical stage asset, FHD-609, a potent and selective heterobifunctional degrader of BRD9

Foghorn Therapeutics Announces Presentation at Upcoming 4th Annual Targeted Protein Degradation Summit

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences.

Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9

Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609

-- First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1/BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML)

Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Steven Bellon, Ph.D., Senior Vice President of Drug Discovery, is scheduled to participate in a panel at the 2021 Wedbush PacGrow Healthcare Virtual Conference, which is being held from August 10-11.

Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Adrian Gottschalk, President & Chief Executive Officer, is scheduled to participate in a panel at the William Blair Biotech Focus Conference 2021, which is being held virtually from July 14-15.

Foghorn Therapeutics to Participate at the William Blair Biotech Focus Conference 2021

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Ian Smith to its Board of Directors effective, April 27.

Foghorn Therapeutics Appoints Ian Smith to its Board of Directors

Foghorn Therapeutics (FHTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Foghorn Therapeutics (FHTX) This Earnings Season?

The stock price of Foghorn Therapeutics Inc. (NASDAQ: FHTX) increased by 36.61% on March 19. This is why it happened.

FHTX Stock Price Increased 36.61%: Why It Happened

CAMBRIDGE, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that the company will present a poster and chair a panel at the American Association for Cancer Research (AACR) Annual Meeting 2021, which is being held virtually from April 10-15.

UPDATE: Foghorn Therapeutics to Present Poster and Chair a Panel at the AACR Annual Meeting 2021

Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021

Axcella Health Inc

Codiak Biosciences

Denali Therapeutics

Evelo Biosciences Inc

Kaleido Biosciences Inc

Seres Therapeutics

Moderna

Rubius Therapeutics Inc

Sana Biotechnology

Sigilon Therapeutics

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it raised $123 million in Series B financing. The round included contributions from funds...

Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target

CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Sam Agresta, M.D., M.P.H, Chief Medical officer is scheduled to participate in a Leukemias panel discussion at the Cowen 41st Annual Healthcare Conference at 11:40 a.m. ET on March 3, 2021.

Foghorn Therapeutics to Participate in the 41st Cowen Annual Healthcare Conference

Guild Holdings

McAfee

Datto Holding

Inari Medical

SelectQuote

US IPO market activity is picking back up ahead of the Thanksgiving holiday, with six IPOs scheduled to raise $3.4 billion in the week ahead. Biotech research product provider Maravai LifeSciences plans to raise $1.3 billion at a $6.6 billion market cap.

U.S. IPO Week Ahead: 6 IPOs Squeeze In Before The Thanksgiving Holiday

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the appointment of Michael LaCascia as its Chief Legal Officer. An accomplished attorney, Mr. LaCascia joins Foghorn with extensive corporate, securities, governance, and transactional expertise within the biotechnology industry.

Foghorn Therapeutics Appoints Michael LaCascia as Chief Legal Officer

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Foghorn. In addition, Foghorn has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Foghorn's common stock is expected to begin trading on The Nasdaq Global Market on October 23, 2020 under the symbol “FHTX.”

Foghorn Therapeutics Announces Pricing of Initial Public Offering

Foghorn Therapeutics Files Terms For $120 Million IPO

Foghorn Therapeutics Inc. set terms for its initial public offering Monday, as the Massachusetts-based company focused on the chromatin regulatory system that leads to gene expression looks to raise up to $127.5 million. The company is offering 7.5 million shares in the IPO, which is expected to price between $15 and $17.

Foghorn Therapeutics sets IPO terms, to raise up to $127.5 million

News for Foghorn Therapeutics Stock (FHTX)